{"id":201,"date":"2021-02-04T12:07:03","date_gmt":"2021-02-04T12:07:03","guid":{"rendered":"https:\/\/ecrinm3.usal.es\/?page_id=201"},"modified":"2021-03-10T12:54:59","modified_gmt":"2021-03-10T12:54:59","slug":"professor-andy-c-rawstron","status":"publish","type":"page","link":"http:\/\/ecrinm3.usal.es\/?page_id=201","title":{"rendered":"Professor Andy C. Rawstron"},"content":{"rendered":"\n<div class=\"wp-block-media-text alignwide is-stacked-on-mobile\" style=\"grid-template-columns:23% auto\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" width=\"289\" height=\"360\" src=\"http:\/\/ecrinm3.usal.es\/wp-content\/uploads\/2021\/02\/Rawstron.jpg\" alt=\"\" class=\"wp-image-470 size-full\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p><em><strong><em><strong>For this project he identifies appropriate participants from the HMDS Outreach monitoring service for patients with early-stage haematological malignancies not requiring immediate treatment. He supervises flow cytometry analyses and ensures appropriate material is stored\/transferred to biobank for the relevant work packages.<\/strong><\/em><\/strong><\/em><\/p>\n\n\n\n<p>Professor Andy Rawstron qualified from Edinburgh University with a BSc in Immunology in 1992. He became a Clinical Scientist at the Haematological Malignancy Diagnostic Service in Leeds and was awarded a Doctor of Philosophy in 2002.<\/p>\n<\/div><\/div>\n\n\n\n<p>Prof Rawstron&#8217;s work into the understanding of CLL, both in terms of defining the nature of Monoclonal B-Lymphocytosis and in developing and standardizing the assessment of minimal residual disease (MRD) in CLL, has been internationally recognized. His work in coordinating a standard approach to MRD analysis in CLL has encouraged close collaboration between many of the laboratories on the cutting edge of CLL research.<\/p>\n\n\n\n<p>Professor Rawstron has a \u00abroutine\u00bb service commitment in the development, selection and interpretation of relevant tests for the diagnosis, treatment and monitoring of haematological malignancy.<\/p>\n\n\n\n<p>Within this role he has developed a National award-winning service for monitoring people with MGUS (monoclonal gammopathy of unknown significance) or early stage CLL.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>For this project he identifies appropriate participants from the HMDS Outreach monitoring service for patients with early-stage haematological malignancies not requiring immediate treatment. He supervises flow cytometry analyses and ensures appropriate material is stored\/transferred to biobank for the relevant work packages. Professor Andy Rawstron qualified from Edinburgh University with a BSc in Immunology in 1992. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":117,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/template-fullwidth.php","meta":[],"_links":{"self":[{"href":"http:\/\/ecrinm3.usal.es\/index.php?rest_route=\/wp\/v2\/pages\/201"}],"collection":[{"href":"http:\/\/ecrinm3.usal.es\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/ecrinm3.usal.es\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/ecrinm3.usal.es\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/ecrinm3.usal.es\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=201"}],"version-history":[{"count":12,"href":"http:\/\/ecrinm3.usal.es\/index.php?rest_route=\/wp\/v2\/pages\/201\/revisions"}],"predecessor-version":[{"id":1284,"href":"http:\/\/ecrinm3.usal.es\/index.php?rest_route=\/wp\/v2\/pages\/201\/revisions\/1284"}],"up":[{"embeddable":true,"href":"http:\/\/ecrinm3.usal.es\/index.php?rest_route=\/wp\/v2\/pages\/117"}],"wp:attachment":[{"href":"http:\/\/ecrinm3.usal.es\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}